BMS 181184

Drug Profile

BMS 181184

Alternative Names: BMY 28762; BMY 28801; BMY 28864

Latest Information Update: 16 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class AIDS vaccines; Antifungals; Antivirals; Fungal vaccines
  • Mechanism of Action Cell membrane modulators; HIV envelope protein gp120 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections; Mycoses; Pneumocystis pneumonia

Most Recent Events

  • 27 Feb 2001 No-Development-Reported for HIV infections treatment in Japan (Parenteral)
  • 27 Feb 2001 No-Development-Reported for HIV infections treatment in United Kingdom (Parenteral)
  • 27 Feb 2001 No-Development-Reported for HIV infections treatment in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top